Shots: The acquisition will enable Boehringer Ingelheim to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the VSV with modified GP platform and cancer […]readmore
Tags : Boehringer
Novartis’s Luxturna (voretigene neparvovec) Receives Health Canada Approval as the First Gene Replacement Therapy for Inherited Retinal Disease Published: Oct 15, 2020 | Tags: approval, Canada, health, Inherited Retinal Disease, […]readmore
Regulatory
Boehringer Ingelheim’s Ofev (nintedanib) Receives FDA’s Advisory Committee Recommendation for
Shots: The FDA’s Arthritis Advisory Committee recommended (10-7 vote) to approve Ofev for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) The FDA’s recommendation is based on P-III SENSCIS […]readmore
Shots: Boehringer Ingelheim (BI) and BeiGene are in collaboration since 2013 for the development of tislelizumab BI BioXcellence is providing CMC services and also helping BeiGene with process & analytical […]readmore